English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Ibogaine for Addiction Recovery: What Families Need to Know Before Booking
Somewhere in the world right now, a mother is sitting at her kitchen table reading message-board threads at 2 a.m., trying to decide whether to send her son to a clinic in Mexico because nothing else has worked. That's the real audience for any honest conversation about ibogaine. Not the wellness-curious. Not the psychonauts collecting experiences. The families and individuals who have run out of options and are weighing a plant medicine most of their doctors have never heard of. Ibogaine sits in a strange category. It's one of the most studied psychedelics for addiction recovery, and simultaneously one of the least talked about in mainstream coverage of plant medicines. People who go through it tend to describe it less as a trip and more as a reckoning. So before anyone clicks the booking button, here's what's actually worth understanding. Ibogaine is the principal alkaloid in the root bark of Tabernanthe iboga, a small shrub native to the forests of Gabon and surrounding countries in west-central Africa. The Bwiti tradition has used iboga ceremonially for generations — for initiation, for ancestral connection, for healing crises that families can't solve on their own. The plant landed on Western radar in the 1960s when a young heroin user named Howard Lotsof took it recreationally and noticed, to his shock, that his withdrawal symptoms had vanished. The story of modern ibogaine treatment starts there. Pharmacologically, ibogaine is unusual. It interacts with multiple receptor systems at once — opioid, serotonin, NMDA, sigma — and its metabolite noribogaine lingers in the body for days. The practical effect, for someone in active opioid dependence, is often a near-complete interruption of withdrawal. That's not marketing language. That's what study participants and clinic data have repeatedly described. Whether the underlying craving stays gone is a separate question, and that's where retreats, integration, and aftercare matter more than the molecule itself. If you've been researching plant medicine for addiction, you've probably bumped into ayahuasca and psilocybin as well. They're not interchangeable. Ayahuasca tends to work through emotional and visionary processing — people often describe confronting memories, family patterns, the roots of why they started using. A psilocybin retreat can do something similar, with a gentler pharmacology and a shorter session. Ibogaine is different in one specific way: it appears to physically reset the opioid receptor system. People come off heroin, fentanyl, oxycodone, and methadone with their withdrawal flattened in ways that other psychedelics don't replicate. Anecdotally, it also helps with stimulant dependence — cocaine, meth — though the mechanism there is murkier. For alcohol, the evidence is mixed and personal. None of these is a magic bullet. The people who do best with any of them tend to be the ones who treat the medicine as the start of the work, not the finish. Here's the part where I'd rather be blunt than reassuring. Ibogaine is the most cardiotoxic of the commonly used plant medicines. It prolongs the QT interval — a measurement of heart electrical timing — and in people with undiagnosed heart conditions, electrolyte imbalances, or certain medication interactions, that can be fatal. There have been deaths. Most have happened at underground or under-equipped settings where pre-screening was inadequate or where someone was still using opioids when they took the dose. What a reputable ibogaine clinic does, at minimum: If a place doesn't do those things — if they wave off the EKG, if there's no doctor, if they're casual about your medication list — walk away. I don't care how good the testimonials are. The medicine is too strong to gamble with. People expect a psychedelic light show. That's not really what ibogaine delivers. The acute experience usually starts an hour or two after dosing and unfolds in phases. The first phase is often called the visionary state — eyes closed, lying down, a stream of images and memories that participants frequently describe as watching their life back, sometimes from unusual angles. There's not much choice involved. The medicine shows you what it shows you. The middle hours can feel physically demanding. Nausea, ataxia, light and sound sensitivity, a heavy body. This is not a dance ceremony. You will be on a mat or in a bed, with a quiet attendant nearby, for most of a day. The introspective phase follows — quieter, more verbal-thought-like, the part where the lessons of the visionary phase get processed. Then a long, sleepless tail of 24 to 48 hours where the body slowly recalibrates and rest is hard to come by. Most people who've done ibogaine for opioid dependence say the same thing afterward: the cravings, the constant background hum of I need to use, is gone or radically diminished when they wake up on the other side. That window is the gift. What you do with it determines whether the recovery sticks. Ibogaine is famous for its post-treatment window — sometimes called the grey day phase — when people report feeling unusually clear, motivated, free of the obsessive pull they lived with for years. That window can last weeks or months. It is not permanent on its own. The receptors come back. The life circumstances that fed the addiction are still there. The relationships, the job, the trauma underneath, the friends who still use — none of that got touched by the molecule. This is the place where so many ibogaine stories take a heartbreaking turn. Someone comes home from a clinic clear-headed, doesn't build the scaffolding (therapy, peer support, a new daily structure, a way to handle the first hard week), and within a few months they're back where they started, sometimes worse. Tolerance drops dramatically after ibogaine, which makes a relapse with the same old dose genuinely dangerous. If you or someone you love is considering this, the question to ask the clinic is not just how is the dosing session? It's what happens for the six months after I leave? Good programs will have an answer. They'll connect you to integration therapists, sometimes to follow-up booster sessions with a lighter medicine like 5-MeO-DMT or microdoses of iboga, sometimes to peer communities. If the answer is essentially you're on your own, treat that as a red flag. Ibogaine isn't for everyone who's struggling. People with a history of significant heart disease, long QT syndrome, recent cardiac events, untreated mental health conditions like active psychosis or bipolar I, or who can't get fully off long-acting opioids beforehand — these are situations where the risk-benefit math doesn't work, no matter how desperate things feel. A good clinic will turn applicants away. That's not them being difficult. That's them keeping you alive. For people who don't fit the ibogaine profile, other plant medicines or clinical pathways may be a better starting point. Sometimes the right move is a psilocybin retreat first, or trauma-focused therapy, or medication-assisted treatment to stabilize before considering anything else. The goal is recovery, not which substance gets credit for it. If you've read this far, you're probably not looking for permission. You're looking for clarity. So here's the honest summary: ibogaine is a serious medicine with a real track record in addiction recovery, particularly opioid dependence, and a real risk profile that demands medical screening and a structured environment. The people it helps tend to be the ones who do their homework, choose a clinic with proper safety standards, and commit to the integration work afterward. The people who get hurt are usually the ones who skipped one of those steps. Talk to people who've been through it. Read accounts that include the difficult parts, not just the success stories. Ask hard questions of any retreat you're considering. And if it feels right after all of that, the curated ibogaine and plant-medicine retreats discussed across the broader recovery space can be browsed on our marketplace here. Whatever you decide, the willingness to look this clearly at the choices in front of you is already part of the work.
MDMA-Assisted Therapy for PTSD: What the Research Actually Shows
Talk to anyone who lives with PTSD and you'll hear a version of the same exhausted story. They've tried the SSRIs. They've done the talk therapy. Some of it helped, a little. None of it did the thing they actually needed it to do — which was to let them sit with what happened without the floor falling out from under them. This is the gap that MDMA-assisted psychotherapy is starting to fill, and it's the reason the conversation around psychedelics and trauma recovery has shifted so sharply in the past few years. We are watching, in something close to real time, the slow legitimisation of a treatment that was banned from clinical use for nearly four decades. For readers weighing whether a psychedelic-assisted approach might help them or someone they love, here's what the picture actually looks like right now. The honest answer is that we haven't had a new pharmaceutical approach to post-traumatic stress disorder in roughly two decades. The standard toolkit — antidepressants, anti-anxiety medication, cognitive processing therapy, EMDR — works for a meaningful slice of patients. For everyone else, it's a long grind of trial and error, side effects, and the quiet despair of feeling like nothing is moving. Part of what makes PTSD so stubborn is structural. Trauma rewires the threat-detection part of the brain so that talking about the event re-triggers it. You can't think your way out of an alarm system. Many patients shut down, dissociate, or simply leave therapy because revisiting the memory feels worse than living around it. And among veterans the cost of this stuckness is staggering — the Department of Veterans Affairs has reported that roughly 18 American veterans die by suicide every day, with PTSD a major driver. So when results from a Phase 3 trial of MDMA-assisted therapy landed in Nature Medicine, the field paid attention. Around two-thirds of participants with severe PTSD no longer met the diagnostic criteria after treatment. That is not a minor effect. That is a number that makes career researchers double-check the data. This is the part most people get wrong, because the cultural image of MDMA is a sweaty warehouse and a water bottle. Clinical MDMA therapy looks almost nothing like that. In the trials, patients work with a co-therapist team — usually two clinicians, often one male and one female — across multiple preparatory sessions before they ever take the medicine. The dosing sessions themselves last six to eight hours. Patients lie down in a quiet room, often with an eye mask and headphones playing a carefully chosen playlist, and they go inward. The therapists are present the entire time, mostly quiet, occasionally checking in or supporting the patient as material surfaces. Then comes integration. After each medicine session, there are several non-drug therapy sessions to make sense of what came up. The standard protocol involves three MDMA sessions total, spaced weeks apart, with talk therapy threaded throughout. The drug is not the treatment. The drug opens a window; the therapy is what walks the patient through it. What participants consistently describe is something rare in trauma work — the ability to look directly at the worst thing that ever happened to them without flooding. The fear response gets quieter. Self-compassion gets louder. People report feeling more empathy, including toward themselves, and a strange capacity to hold grief, rage, and tenderness in the same hour without coming apart. Short answer: not yet for general clinical use, but the regulatory path is further along than most people realise. The FDA gave MDMA-assisted therapy Breakthrough Therapy designation, which is the agency's way of saying this looks promising enough to fast-track. Several jurisdictions have moved on their own — Australia, for example, has already approved prescribed MDMA for PTSD under tightly controlled conditions. In the United States, the road has been bumpier than advocates hoped. The FDA's advisory committee raised concerns in 2024 about trial design and the difficulty of blinding a study where participants obviously know whether they got the active drug. Additional research is underway. Most observers now expect a fuller approval picture to settle within the next couple of years, rather than the original optimistic 2023 target. For someone suffering right now, that timeline can feel maddening. A few legitimate options exist in the meantime: This is the part of the conversation that gets skipped in breathless coverage, and it matters. MDMA-assisted therapy is powerful, which means it can also be powerfully wrong for the wrong person. People with a personal or strong family history of psychosis or bipolar I are generally excluded from trials, because psychedelic-style experiences can destabilise vulnerable nervous systems. Certain heart conditions are a contraindication — MDMA raises blood pressure and heart rate. SSRIs and a handful of other medications interact badly with MDMA and have to be carefully tapered under medical supervision before any session, never on someone's own initiative. And then there's the psychological readiness piece, which no blood test will catch. Bringing buried trauma to the surface is the point of this work. If someone has no support system, no follow-up therapy lined up, and no plan for the weeks after the session — when integration is happening whether you're ready or not — they can end up more raw than when they started. The medicine is a catalyst. The container around it does the actual healing. MDMA is not a plant medicine in the traditional sense — it's a synthesized compound, first patented in 1912 and developed for psychiatric use in the 1970s. But the renaissance it represents is part of a broader shift. Psilocybin, ayahuasca, ibogaine, and 5-MeO-DMT are all moving through their own research pipelines and cultural reappraisals. The same basic insight underlies all of them: certain altered states, held inside a skilled therapeutic relationship, can shift things that conventional treatment cannot reach. This doesn't make psychedelics a cure-all. It doesn't make every retreat trustworthy, or every facilitator competent. What it does mean is that the question is no longer whether these medicines work — the evidence on that is increasingly clear — but how to deliver them responsibly, who they help most, and how to keep the work grounded as it scales. If you're sitting with PTSD, or watching someone you love sit with it, the most useful thing you can do right now is get informed. Read the published trials. Talk to a psychiatrist who actually knows this space. Look at ketamine-assisted options that are legal today. And if you're drawn to the broader world of psychedelic healing — including the plant-medicine traditions that have worked with trauma long before clinical trials existed — a thoughtfully chosen retreat can be one part of a longer recovery arc. For readers who want to take this further, a range of trauma-informed plant-medicine and psychedelic retreats can be browsed on our marketplace here. Whatever you decide, decide slowly. The medicines aren't going anywhere, and the best work in this space rewards patience.
Ibogaine Aftermath: What to Do When Side Effects Linger Past Two Weeks
Two weeks after an ibogaine session and you still feel… off. Heart fluttering when you climb stairs. Sleep that comes in shards. A weird metallic fatigue that no green juice is touching. If that's where you are right now, take a breath. You're not alone, you're not broken, and you're also not necessarily fine — so let's talk about what's actually happening. Ibogaine is one of the heaviest hitters in the plant medicine and psychedelics world, with a deserved reputation for interrupting opioid addiction in a single session. But it's also the one most people underestimate on the back end. The trip ends. The recovery doesn't. And nobody at the retreat tends to send you home with a clear map for week two, week three, or month three — which is exactly when a lot of folks start quietly panicking. Most psychedelics clear your system in hours. Ibogaine does not play by those rules. The active compound metabolizes into noribogaine, which hangs around in fatty tissue and can keep influencing your nervous system for days, sometimes weeks. People report mood shifts, ataxia (that drunk-walking feeling), tinnitus, and cardiac irregularities well past the point they expected to feel normal. This isn't a bug — it's part of why ibogaine works for addiction recovery in the first place. The slow taper of noribogaine seems to ease the withdrawal cliff that breaks most people trying to come off opioids. The trade-off is that you're essentially convalescing from something the body genuinely had to work to process. Treat it like minor surgery, not like a hangover. Half-life estimates vary wildly between individuals. Body composition, liver enzymes (specifically CYP2D6), dose, and what you came in with all matter. Someone with a slow CYP2D6 phenotype can metabolize ibogaine dramatically slower than the person who sat next to them in ceremony. Two people, same dose, very different week-three experiences. Here's the rough territory most people land in. Not medical advice — just patterns I've heard from facilitators, integration coaches, and dozens of people who've come through the other side. Most of this is your nervous system recalibrating. The neural pathways that ibogaine seems to soften and rewire don't reset on a tidy schedule. If a friend who's never done plant medicine asks how you are and you say “still catching up to myself,” that's roughly the right answer for several weeks. Now the part nobody loves talking about. Some symptoms warrant a doctor — not a shaman, not a Reddit thread, an actual cardiologist or GP. Ibogaine has well-documented effects on the QT interval (a measurement of heart rhythm), and on rare occasions those effects don't snap back to baseline as fast as they should. Get medical attention if you're experiencing any of the following past the two-week mark: Ask for an ECG. Mention ibogaine specifically — most cardiologists won't have heard of it, but they'll know what to do once you describe what was taken and when. Bring documentation from your retreat if you have it. If you don't, write down what you remember: dose (in mg or flood/booster terminology), date, body weight at the time, any pre-screening labs they ran. This information will save you and the doctor a lot of fumbling. The instinct after a heavy psychedelic experience is to throw everything at the wall — supplements, gym sessions, cold plunges, three different therapists. Resist. Your system is already doing a lot. The kindest thing you can do is reduce inputs, not pile them on. What actually helps in the first month post-ibogaine: What to avoid: alcohol (full stop, for at least a month), other psychedelics (no “topping up” the experience, this is how people get hurt), SSRIs unless your prescriber has cleared the timing, and any stimulant — including pre-workout powders — until you've had a clean cardiac check. Here's the thing nobody tells you when you're booking an ibogaine retreat: the ceremony is the easiest part. The hard, slow, unsexy work is what happens in the weeks and months after, when you're back in your kitchen wondering if anything actually changed. People who do well long-term tend to share a few habits. They don't try to interpret the experience too quickly. They write things down without forcing meaning onto them. They stay connected to a small handful of people who get it. And they treat the post-ceremony months as protected time — they don't book a vision quest in Peru three weeks after their ibogaine session because they read about it on a forum at 3 a.m. If you came to ibogaine for opioid addiction, the integration window is also when relapse risk quietly creeps back. The window of reduced craving is real, but it's not infinite. Use the time. Build the structure — meetings, sponsor, therapist, exercise, accountability — that the medicine cleared space for. The medicine opened the door. You still have to walk through it, every day. An honest word: ibogaine isn't magic. It's an extraordinary tool with real risks, and it's the start of a process, not the conclusion of one. People who treat it as a single transaction — pay the money, take the medicine, problem solved — tend to be the same people who end up disappointed three months later, or worse, back in the patterns they came to interrupt. Some of the master plants and psychedelic medicines in this space work better as a sequence rather than a one-off. Ayahuasca after ibogaine. Psilocybin for ongoing depression work. San Pedro for grounding and integration. None of this is prescription — it's the lived pattern from people who've made meaningful changes stick. The medicine that finally moved something in you may not be the same medicine that helps you keep that ground. For readers wanting to take their healing further, a curated range of ibogaine, ayahuasca, and other plant medicine retreats can be browsed on our marketplace here. Take your time choosing — a good retreat will welcome your questions about screening, aftercare, and what happens at week three.
Life After Ibogaine: Why Your Post-Treatment Plan Matters More Than the Flood
There's a quiet truth in the ibogaine world that nobody puts on the brochure: the medicine doesn't do the work. It opens the door. What happens after you walk through it — the weeks and months when you're back home, back in your kitchen, back in your old life — is where the actual healing lives or dies. And most people, including most people running clinics, don't talk about this part nearly enough. If you're researching ibogaine for addiction recovery, depression, or some other stubborn pattern you can't seem to outrun, this is the piece I wish someone had handed me before I booked a thing. Not the success stories. Not the trip reports. The plan. Because the plant medicine itself is only the first act. Ibogaine is a long-acting psychedelic alkaloid from the iboga root, used traditionally in Bwiti ceremonies in Gabon and, more recently, in clinical settings for opioid dependence and other addictions. A full session can last 24 to 36 hours. People describe a dreamlike review of their life, sometimes brutally honest, sometimes tender, sometimes both in the same five minutes. Here's what it tends to do well: it interrupts withdrawal from opioids in a way nothing else really does, it loosens the grip of compulsive patterns, and it gives many people a few weeks of unusual clarity afterward — what some clinicians call the afterglow or the window. That window is real. It's also temporary. What ibogaine doesn't do: rebuild your relationships, find you a new job, teach you how to feel boredom without reaching for something, or replace the friends who only know you as the version of you that used. None of that comes in the capsule. If you treat the session like a cure, you'll be disappointed within three months. If you treat it as the most powerful tool you've ever been handed for the work you still have to do — that's where the change happens. For roughly four to twelve weeks after a session, many people report a noticeable shift. Cravings are quieter. Old triggers feel further away. There's a softness, sometimes a strange grief, sometimes a surge of motivation. Your nervous system is, in essence, recalibrating. This window is gold. It's also the easiest thing in the world to waste. People waste it in predictable ways. They go back to the same apartment, the same routines, the same five friends, and assume the new feeling will hold on its own. It rarely does. The mind has a long memory for habit, and the second the afterglow fades — and it does fade — the old grooves are still right there waiting. The people I've watched genuinely change their lives after ibogaine all did something during that window. They moved. They quit a job. They started therapy. They cut off three numbers. They picked up a daily practice and stuck with it past the point where it was novel. The medicine gave them traction; they used it to climb. A good integration plan isn't a vision board. It's a list of specific, concrete things you've already committed to before you ever sit down for the session. Vague intentions evaporate. Calendar entries don't. Here's the shape of one that actually works: None of this is glamorous. None of it involves a second ceremony. That's the point. The most common post-ibogaine failure I've seen isn't relapse in the dramatic sense. It's something quieter: people get so attached to the experience itself that they keep chasing the next session instead of metabolizing the one they already had. Six months later they're booking iboga number three and they still haven't called the therapist. Plant medicines can become their own kind of bypass. The trip becomes the identity. The retreat becomes the vacation from your actual life. If you find yourself planning the next ceremony before you've done anything with the last one, that's worth paying attention to. The work was never the medicine. The work is Tuesday morning at 9 a.m. when nobody's watching. This isn't an argument against multiple sessions — some people genuinely benefit from them, spaced out over years. It's an argument against using ceremony as a way to avoid the slow, unsexy labor of changing how you live. If you're still in the research phase, here's a filter that will eliminate maybe sixty percent of options instantly: ask the provider what their post-treatment support looks like. A serious clinic or facilitator will have a real answer — integration calls, a structured follow-up program, a network of aftercare resources, ideally a relationship with therapists or coaches they refer to. A sketchy one will say something like "we send you home with intentions" and change the subject to deposit policies. Other questions worth asking before you commit: If the answers feel rehearsed or evasive, walk. The plant-medicine space has both genuine healers and people who learned the right vocabulary last year. You're trusting them with your nervous system for thirty-something hours. Due diligence isn't paranoid; it's the bare minimum. Nobody warns you about the airport. You step off the plane after a week in the jungle or at a clinic somewhere, and the world is exactly as you left it. Same advertisements. Same traffic. Same people who don't know what you've just been through and wouldn't entirely understand if you tried to explain. This re-entry is harder than the session for a lot of people. Plan for it. Don't schedule a giant work week the day after you land. Don't expect your partner to immediately understand the version of you that came back. Give yourself a few days of soft landing — quiet, nature, simple food, no big decisions — before you try to slot back into normal life. And keep talking about it, in the right contexts. Integration groups exist online and in person specifically because most of the people in your daily life are not equipped to hold what you're processing. That's not a judgment of them. It's just true. Find the rooms where it makes sense to speak honestly. Ibogaine, at its best, is a lever. It moves things that wouldn't otherwise budge. But a lever needs something to push against, and that something is the life you build in the months and years after. The people I know who are five or seven years out from a session that genuinely changed them all say some version of the same thing: it was the start, not the finish. The work didn't end when the visions stopped. If you're considering this path for addiction, trauma, or a depression that hasn't responded to anything else, take the choice seriously — both the choice to go, and the choice of what to do when you come back. The session is one weekend. The aftercare is the next two years. Build for that. For readers who want to take this further, a range of vetted ibogaine and plant-medicine retreats with integration support can be browsed on our marketplace here.
Psilocybin for Alcohol Addiction: One Woman's Story and What the Research Shows
Kimberly had her first drink at fourteen, at a slumber party somewhere in the late Sixties. The other girls sipped and giggled. She drank until the housekeeper had to chase her around the yard to herd her back inside. She knew something was different about her relationship with alcohol from that very first night — and forty years later, after a breast cancer diagnosis and a quiet kind of desperation, she finally found something that worked. It wasn't a twelve-step program. It wasn't rehab. It was a single guided session with psilocybin, the psychoactive compound in magic mushrooms, taken inside a clinical trial at NYU Langone. Her story is one of the more striking anecdotes to emerge from the growing body of research into psychedelics and addiction recovery. And while one woman's experience is not a treatment plan, it points at something researchers have been quietly building evidence for: that plant medicine, used carefully and with proper support, can interrupt the deeply grooved patterns that keep people drinking. Kimberly's drinking didn't start the night of the slumber party. After that, she stayed away from alcohol — her parents were both addicted, and even at fourteen she suspected she'd inherited the same wiring. The break held until college, and really took hold when she landed her first job as a TV producer in New York at twenty-one. The industry ran on after-work drinks. Three glasses of Chardonnay at happy hour. Then three glasses at home. Then a bottle alone until she, in her words, dozed off. (A polite way of saying blacked out.) She left the industry at thirty-six. The drinking didn't leave with her. By forty-four it was every day, and there was, she said, no such thing as moderation. The strange thing — and anyone who's lived near addiction will recognize this — is that her work never visibly suffered. The damage was internal: poor sleep, low-grade exhaustion, the slow erosion of joy in things she used to love. The kind of drinking nobody at the dinner party notices, but the drinker can't ignore. Then came the cancer diagnosis. Even one drink a day raises the risk of breast cancer, and Kimberly had been drinking far more than that for decades. She described it as the ultimate wake-up call — proof, she felt, that her body had been keeping score. Something had to change, and the old methods hadn't moved the needle. The NYU trial enrolled ninety-three people with alcohol use disorder. The protocol pairs psilocybin sessions with twelve weeks of talk therapy — the substance is not the whole treatment, just one piece of a larger structure. Participants received two dosing sessions of either psilocybin or an antihistamine placebo designed to mimic some surface sensations of a trip, then a third session in which everyone was offered psilocybin if it was medically safe. This is worth pausing on, because it's a feature of every legitimate psychedelic-assisted program: the medicine is not a pill you swallow and walk away from. There is preparation. There is a long session held in a quiet room with trained guides. There is integration afterward — weeks of therapy where the experience gets unpacked, examined, applied to daily life. Strip any one of those layers away and you've got something much closer to recreational drug use than treatment. The published results in JAMA Psychiatry showed that participants who received psilocybin had significantly fewer heavy-drinking days over the thirty-two-week trial than those who got the placebo. Not a cure for everyone, not a magic bullet, but a meaningful effect from two guided experiences plus therapy — which, compared to standard addiction treatments, is a remarkably short intervention. Before swallowing the pill, Kimberly held hands in a circle with two researchers and named her intention out loud. Address the drinking issue. Setting intention before a ceremony or session is standard practice across both clinical psychedelic work and traditional plant medicine traditions — and it matters more than people realize. The medicine seems to follow the question. She lay down with an eye mask and a curated playlist. At some point her vision started wobbling. Then a TV cue card appeared in her mind's eye — the kind she'd worked with for years in the studio — with one word on it: Drinking. She sat up and said, to no one in particular, All the portals are open. What is it you want me to know? What followed she described in spatial terms — a staircase, a door at the top, oppressive clouds overhead that her mind labeled as the alcohol itself. She walked up, opened the door, stepped into the light. And then she had what she called a conversation with herself, in which she decided, simply and finally, that she would never drink again. That was April 2018. She hasn't had a drink or a craving since. Her family used the word miraculous. She uses the word reset. The interesting question is why a single experience can do what years of willpower couldn't. Researchers studying psychedelics for addiction recovery have a few overlapping theories: None of this means the psychedelic is doing the work alone. It seems to crack something open. Therapy and intention do the rest. Psilocybin isn't the only psychedelic showing promise for addiction. Ibogaine — derived from the iboga shrub in West Africa — has a longer underground history with opioid and alcohol dependence, and clinics in Mexico and Costa Rica have been running structured programs for years. Ayahuasca, the Amazonian brew, has been used ceremonially for centuries and is now drawing people who specifically want to work on addictive patterns, often alongside what traditional practitioners call master plants — tobacco, bobinsana, ajo sacha and others used in dieta to support deep psychological work. These are different medicines with different risk profiles and different cultural contexts. Ibogaine carries real cardiac risk and requires medical screening. Ayahuasca involves multi-night ceremonies and a strict diet. Psilocybin sessions, currently legal only in narrow contexts like the Oregon program or clinical trials, are shorter and chemically simpler. Choosing between them — if you're choosing at all — is a serious decision that depends on your history, your goals, and the quality of the team holding the container. A few honest things worth knowing before you book anything: Kimberly's case is unusually clean — a single session, total cessation, no relapse. That's not the average outcome. The trial showed strong effects across the group, but plenty of participants still drank, just less. Some needed booster sessions. Real recovery, for most people, is a long arc with a few catalysts inside it. A psychedelic session can be one of those catalysts. It is rarely the whole story. If you've read this far, you're probably weighing something concrete in your own life. Take the time to research properly, talk to a doctor, and choose facilitators who screen carefully and offer real integration support. For readers who want to look at structured options, a range of vetted psilocybin and plant-medicine retreats focused on addiction recovery can be browsed on our marketplace here. Whatever path you choose, choose it with eyes open — that, more than the medicine itself, is what tends to make the difference.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Why Sobriety Alone Isn't Enough: Ibogaine and the Long Road After Addiction
There's a moment, somewhere around day ninety of being clean, when most people in recovery quietly realize something nobody warned them about. The drug is gone. The drink is gone. And yet — the life underneath it is still there, exactly as miserable as the day they started using. Sobriety, it turns out, isn't the destination. It's the front door. This is the part of the conversation that ayahuasca, ibogaine, and psilocybin retreats sometimes gloss over. Plant medicine for addiction is genuinely powerful — there's a reason ibogaine, in particular, has built such a fierce reputation among people who've tried everything else. But anyone who's sat across from a former heroin user a year after their flood dose, or talked to a drinker six months out from their first ayahuasca ceremony, will tell you the same thing: the medicine starts the work. It doesn't finish it. Ibogaine, extracted from the root bark of the Tabernanthe iboga plant, has one of the strangest pharmacological profiles in the psychedelic world. People who take a full flood dose for opioid dependence routinely report that physical withdrawal — the kicking, the sweating, the bone-deep agony — simply doesn't arrive. Cravings drop off a cliff. The window of clarity that opens can last weeks or months. That's not nothing. For someone who's been chained to fentanyl or alcohol for a decade, having the chemical hooks pulled out in 24 hours feels like a miracle. And it kind of is. But here's where the trouble starts: the medicine doesn't teach you how to handle a Tuesday afternoon when you're bored, lonely, and twenty minutes from your old dealer's neighborhood. It doesn't show you how to sit with your mother at Thanksgiving without wanting to disappear. It doesn't rebuild the friendships, the routines, the sense of meaning that addiction systematically demolished. The reset is real. The rebuild is on you. One of the more honest things I've heard from a longtime ibogaine provider in Mexico: "Most of the people who relapse come back six months later thinking the medicine failed them. It didn't. They went home and did nothing different." This is the trap. The post-ceremony glow is enormous. You feel rewired. You feel like a new person. And for a few weeks, you basically are — your nervous system is recalibrated, your mood is brighter, the constant low hum of craving is quiet for the first time in years. It's easy to mistake this for being healed. Then life resumes. The bills come. The old social circle calls. The brain, which never actually forgets the reward pathway it spent years carving, starts whispering again. And if nothing in your daily life has structurally changed — no new community, no therapist, no work on the underlying pain — that whisper gets louder, fast. Talk to people who've stayed clean five or ten years after a psychedelic-assisted reset, and you start to hear the same things over and over. None of them are glamorous. Notice what's not on this list: another retreat. Another ceremony. Another peak experience. The temptation to chase the medicine — to go back to Costa Rica every six months hoping for another reset — is one of the more interesting forms of avoidance the recovery world has invented. It looks spiritual. It often isn't. The traditions these medicines come from have been clear about this for centuries, even if the modern retreat circuit isn't. In the Shipibo lineage, ayahuasca is one of dozens of master plants, and dieta — the months of isolation, restricted food, and apprenticeship with a single plant — is the actual healing work. The brew is the door. The dieta is what happens inside. The Bwiti tradition that gave the world ibogaine treats the medicine as part of an initiation that reshapes a person's place in their community. It's not a weekend. It's a turning point inside a longer arc, surrounded by elders, songs, and obligations that continue after the ceremony ends. The Western framing — fly in, drink the medicine, fly out, post about it on Instagram — strips the medicine of the scaffolding that made it work in the first place. That doesn't mean the retreats are useless. Plenty of them do good, careful work and send people home with real preparation and integration support. But the burden is shifted: you, the participant, have to build the rest of the scaffolding yourself, in a culture that mostly doesn't believe it exists. If you're researching ayahuasca or ibogaine retreats specifically for addiction recovery, the questions to ask are not about the jungle, the food, or the facilitator's lineage. Ask these instead: The places worth your money will have thought about all of this. The ones that haven't will change the subject back to the ceremony itself, because that's what they're selling. Recovery, with or without plant medicine, is a years-long project that mostly happens in unsexy ways. A morning walk. A phone call to someone who's been through it. A boring Wednesday where nothing collapses. A slow rebuilding of the muscle that lets you tolerate being a person without numbing it. Ibogaine can hand you the keys. Ayahuasca can show you the map. Psilocybin can soften the wall you've been hitting your head against for fifteen years. None of them can drive the car for you. If you're considering a retreat as part of your own recovery — and many people genuinely benefit from one — go in with both eyes open. Plan the year that comes after before you plan the trip. Build the support before you build the suitcase. Treat the ceremony as the beginning of the work, not the end of it. For readers exploring this path more seriously, a range of vetted ibogaine and ayahuasca retreats focused on addiction recovery can be browsed on our marketplace here. Whatever you choose, choose with the long view in mind — the medicine is the easy part.
Ibogaine for Opiate Addiction: What Recovery Actually Looks Like Six Months Later
Six months. That's roughly how long it takes for the dust to settle after an ibogaine treatment for opiate addiction — long enough to know whether the rewiring held, and long enough to be honest about what didn't. If you're researching ibogaine because seven years of opiates (or three, or fifteen) have stopped feeling like a choice, this is the article I wish someone had handed me before I booked anything. I've sat with people in the days after their flood dose. I've talked to facilitators who've run hundreds of sessions, and to clients who came back six months, two years, five years out. What follows isn't a hype piece. It's what actually tends to happen — the good, the weird, and the parts that get glossed over on retreat websites. Ibogaine is an alkaloid from the root bark of the Tabernanthe iboga shrub, used ceremonially in Gabon for centuries by Bwiti practitioners. Somewhere in the 1960s a heroin-using teenager in New York noticed that a single dose interrupted his withdrawal almost entirely. That accidental discovery is, more or less, why ibogaine is now a fixture in serious conversations about plant medicine and addiction recovery. Here's the part that grabs people's attention: a properly administered flood dose can shut down acute opiate withdrawal in a matter of hours. Not soften it. Shut it down. People who've been dope sick dozens of times describe waking up the next day without the usual bone-deep cravings — sometimes for weeks, sometimes for months. That's not a marketing claim; it's consistent enough across reports and the limited clinical literature that researchers in Mexico, New Zealand, and Brazil have built treatment programs around it. But ibogaine is not a magic eraser, and anyone selling it that way is either naive or lying. It's a tool — a powerful, demanding, occasionally dangerous tool — that opens a window. What you do inside that window is the actual work. Flood-dose ibogaine isn't a recreational psychedelic experience. Don't go in expecting beauty. The first few hours after dosing are usually spent flat on your back, eyes closed, in what's often called the “waking dream” state — a long, slow review of your life delivered in fragments. People report watching themselves at age six. At nineteen. At the worst moment they’ve ever caused. It's exhausting and frequently uncomfortable. Then comes the long, gray middle. Hours twelve through thirty-six are typically the hardest physically — ataxia (you genuinely cannot walk), nausea, sensitivity to light and sound, and a strange tinnitus-like buzz that fades over days. A medical team should be on you the whole time, monitoring heart rhythm via EKG, because ibogaine prolongs the QT interval and that's where the real risk lives. Cardiac screening before treatment isn't optional. It's the line between a credible clinic and one to walk away from. By day three most people can stand, eat a little, and have a real conversation. The cravings are usually gone or dramatically reduced. And then — and this is the part nobody prepares you for — you go home. The first month is strange in a quiet way. The compulsion to use is missing. The morning routines tied to using fall apart because there's nothing to chase. Sleep is patchy. Many people describe a low-level afterglow — a sense that something in the wiring genuinely shifted — alongside an unfamiliar emotional rawness. Old grief shows up. Stuff you stuffed down with opiates for seven years doesn't stay stuffed when the opiates are gone. This is where the work begins. Most facilitators will tell you ibogaine gives you roughly a three-to-six-month window where the neural conditions for change are unusually favorable — dopamine receptors are resensitizing, the default mental ruts feel less grooved, decisions you couldn't make for years suddenly feel obvious. If you waste that window, the window closes. What actually fills the window for people who stay clean tends to look like: People who skip all of this and assume the medicine did the job tend to relapse around month two or three. Not because ibogaine failed. Because they treated a window like a finish line. You've probably also read about ayahuasca for addiction, psilocybin trials for alcohol use disorder, and kambo as a complementary practice. They are not interchangeable. Ibogaine is unique in its specific action against opiate withdrawal — no other plant medicine reliably does that. Ayahuasca, by contrast, tends to work on the emotional and spiritual layer underneath the addiction: the trauma, the shame, the patterns. Many people in long-term recovery from opiates do ibogaine first to break the physical dependence, then incorporate ayahuasca ceremonies later for the deeper trauma work. Psilocybin is showing real promise for alcohol and tobacco addiction in clinical trials, but the data on opiates is thinner. San Pedro and other master plants tend to support the slower, longer integration work rather than the acute reset. None of these are weekend hobbies. All of them deserve preparation, screening, and aftercare. Ibogaine is legal in some countries (Mexico, Costa Rica, New Zealand, the Netherlands, Brazil, South Africa), unscheduled in others, and a Schedule I substance in the United States. That patchwork means quality varies wildly. There are excellent medically supervised clinics. There are also outfits running flood doses out of rental houses with no EKG, no nurse, and no plan if something goes wrong. The latter kill people every year. A short checklist before you wire any deposit: Also: be suspicious of anyone who guarantees you won't relapse. Nobody can promise that. Anyone who does is selling something other than honesty. Among the people I've followed past the half-year mark, the pattern is roughly this. Around a third are completely opiate-free and describe their life as functionally unrecognizable from before. Another third are mostly clean but have had one or two slips, usually around month two, and either course-corrected or did a follow-up treatment. The last third relapsed meaningfully — often the people who did no integration work, or who returned to the exact environment that produced the addiction. That's not a brochure-friendly statistic. It is, however, dramatically better than the outcomes from standard medication-assisted treatment alone, and the people who do recover tend to describe a quality of recovery that feels qualitatively different — not white-knuckled abstinence, but a genuine loss of interest in the drug. That's the part that's hard to capture in any clinical trial. If you're standing where I was standing two years ago — exhausted by your own life, tired of every previous attempt, quietly Googling at 3 a.m. — ibogaine is worth taking seriously. So is the work that has to follow it. For readers who want to take this further, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Read carefully, ask hard questions, and trust the providers who answer them without flinching.
Ibogaine for Addiction Recovery: What 36 Days Clean Actually Looks Like
There's a particular kind of quiet that settles in around the fifth week after an ibogaine treatment. The acute work is done. The visions have faded into something you half-remember, half-feel. The cravings — if they're going to creep back — usually start testing the locks somewhere around here. This is the stretch nobody warns you about, and it's also the stretch that decides whether the whole thing took. People come to ibogaine for one reason more than any other: they want out of an addiction they've tried to escape a dozen times before. Opioids, mostly. But also alcohol, stimulants, benzodiazepines, and the harder-to-name patterns that don't show up on a tox screen. The plant medicine community has long whispered about ibogaine as the closest thing we have to a reset button. The science is starting to catch up. And the lived experiences shared by people in early recovery — the raw, unpolished ones — are often more useful than any clinical write-up. Ibogaine is an alkaloid found in the root bark of the Tabernanthe iboga shrub, native to Central Africa. In the Bwiti tradition of Gabon, it's used in initiation ceremonies that have nothing to do with addiction. Western medicine stumbled onto its anti-addictive properties almost by accident in the 1960s, when a heroin user named Howard Lotsof noticed his cravings simply weren't there after taking it. What happens neurologically is still being mapped, but the broad strokes are these: ibogaine appears to reset opioid receptors, interrupt the conditioned cravings that keep relapse cycles spinning, and — most strikingly — produce a long, dreamlike review of your own life. Many people describe it less as a trip and more as an interrogation. Memories surface unbidden. Decisions get re-examined. The reasons you started using in the first place tend to show up in the room with you. It's not gentle. A full flood dose lasts somewhere between 24 and 36 hours, with the most intense phase usually in the first 8 to 12. People describe nausea, ataxia (you can't really walk), and a relentless interior monologue. The phrase you hear over and over from people who've done it: I wouldn't do it again, and I wouldn't undo it. Here's roughly what the recovery arc looks like for someone using ibogaine to come off opioids or another long-running dependency. Individual experiences vary enormously, but patterns repeat: That milestone — the one-month-plus mark — is when people on recovery forums tend to post for the first time. They want to mark the moment. They also want to know if what they're feeling is normal. The answer is almost always yes. Here's the part the more honest practitioners will tell you and the marketing brochures usually won't: ibogaine is a powerful interrupt, not a cure. The treatment can pull you out of physical dependence and give you a remarkably clear view of the patterns that drove your use. But it doesn't rebuild your social life. It doesn't fix the relationship that's been collateral damage. It doesn't pay your rent or restructure your evenings. The people who stay clean — and there are many — almost universally do three things after treatment: A treatment without integration is, as one facilitator I spoke with put it, like getting a heart transplant and skipping physical therapy. The surgery worked. That doesn't mean you can run yet. This is where the stakes get serious. Ibogaine has real cardiac risks — it can prolong the QT interval, and people with undiagnosed heart conditions have died during treatment. It's a Schedule I substance in the United States, which means legitimate treatment happens primarily in Mexico, Costa Rica, the Netherlands, South Africa, and a handful of other jurisdictions where it's legal or unscheduled. A few things to look for, and a few red flags that should make you walk away: Ask to speak with past clients. A confident provider will connect you. Ask what their protocol is if something goes wrong medically. Ask how many treatments they've done and what their experience is with your specific substance of dependence — ibogaine for opioid recovery is well-mapped; ibogaine for stimulant or alcohol recovery is a different conversation. Most people arrive thinking the substance is the problem. By day three of an ibogaine experience, most have revised that opinion. The substance is what they were using to manage something — grief, an old wound, a chronic anxiety, a sense of not belonging in their own life. Ibogaine has a particular knack for showing you the thing underneath the thing. That can be the most valuable part of the whole experience. It can also be the hardest. Reading other people's accounts of post-treatment life, you notice a pattern: the addiction was loud, but underneath it was often a depression, a trauma, a relational pattern they hadn't known how to look at. Sobriety made all of that visible. The work of recovery, properly understood, is the work of attending to what was hiding behind the using. This is why integration matters so much, and why a one-week clinic stay is the beginning of a longer process — not its conclusion. Some people pair ibogaine with subsequent work using other plant medicines, ayahuasca being the most common, often months later, to keep deepening the inner work. Others go in the opposite direction and lean entirely on therapy, community, and stillness. Both paths can work. Neither works automatically. Talk to people who've done it. Read the long, honest accounts — the ones that include the hard parts, not just the breakthroughs. Speak with at least two providers before you choose. Get cleared by a cardiologist who knows what you're planning. Don't go alone if you can help it; having someone meet you on the other side, even just for the first week, matters more than most people realize. And give yourself a real plan for the months after. Where will you live? Who will you call when it's hard? What will you do with the time you used to spend using? These questions are not optional. They're the actual treatment, in a way the substance itself can never be. For anyone weighing this seriously, a curated selection of ibogaine and plant-medicine retreats with vetted medical protocols can be browsed on our marketplace here. Thirty-six days is a real milestone — but it's a beginning, not a finish line, and the people who treat it that way are the ones who tend to still be free at day three hundred and sixty.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
